Arrowhead prices offering at $104M; FDA clears rectal delivery device from Hospi;

> Arrowhead ($ARWR) priced an underwritten offering of 5.5 million shares at $18.95 per share. The RNAi therapeutic company expects to pull in about $104 million. Release

> The FDA cleared Hospi Corporation's Macy Catheter device for rectal administration of liquid medication. More

The Wall Street Journal highlighted Mir Imran's Rani Therapeutics, which, backed by Google ($GOOG), is developing a robotic pill to replace injections. Profile